(redirected from Peregrine Pharmaceuticals, Inc)
PPHMPeregrine Pharmaceuticals, Inc (stock symbol)
PPHMPanhandle Plains Historical Museum (Canyon, TX)
PPHMParts Per Hundred Million
PPHMPatterson Palmer Hunt Murphy (law firm; New Brunswick, Canada)
PPHMPort Perry Half Marathon (Canada)
References in periodicals archive ?
* Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) shares declined 18.69 percent to close at $4.35 after the company reported a Q2 loss of $12.6 million on revenue of $12.8 million.
A biopharmaceutical firm that wants to enhance patient lives by delivering high quality biological products through its contract development and manufacturing organization (CDMO) services and by advancing its novel R&D pipeline, Peregrine Pharmaceuticals, Inc., has announced that it has entered into an exclusive licensing deal with University of Texas (UT) Southwestern Medical Center for a new exosome technology that has potential application as a simple blood test for the detection or monitoring of cancer.
[USPRwire, Sun Nov 22 2015] Global Markets Direct's, 'Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Peregrine Pharmaceuticals, Inc.'s pharmaceutical research and development focus.
Peregrine Pharmaceuticals, Inc. has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, late-stage trial.
Avid Bioservices is cGMP manufacturing services company and a subsidiary of Peregrine Pharmaceuticals, Inc (NasdaqCM:PPHM), a private clinical-stage specialty biopharmaceutical company.
Peregrine Pharmaceuticals, Inc. (Tustin, CA) reported the issuance of a United States patent with broad claims covering vascular imaging applications for phosphatidylserine (PS)-targeting antibodies.
Peregrine Pharmaceuticals, Inc., Tustin, Calif., has submitted its investigational new drug application (IND) to the U.S.
Peregrine Pharmaceuticals, Inc (Nasdaq: PPHM) and Affitech AS will collaborate on the production of human antibodies for Peregrine's Vascular Targeting Agent (VTA) and anti- angiogenesis.
Companies Mentioned in this Report: Vical Incorporated, Sanofi-Aventis, GenVec, Inc., CEL-SCI Corporation, Mymetics Corporation, Nutra Pharma Corporation, Peregrine Pharmaceuticals, Inc., Pevion Biotech Ltd, Oryzon, Functional Genetics, Inc., Colby Pharmaceutical Company, Osel Inc., AlphaVax, Inc., Romark Laboratories, L.C., Chimerix, Inc., NanoBio Corporation, ImmunoVaccine Technologies Inc., Immune Design Inc., PepTcell Limited, Vaxart, Inc., Genocea Biosciences, Inc., Profectus BioSciences, Inc., 3-V Biosciences, Inc., Spider Biotech S.r.l., Kala Pharmaceuticals, Coridon Pty Ltd
Peregrine Pharmaceuticals, Inc. (Tustin, CA) reported the issuance of a United States patent that further strengthens the company's intellectual property leadership in the field of phospholipid-targeting agents for the treatment of life-threatening diseases.
Peregrine Pharmaceuticals, Inc. (Tustin, CA), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection (HCV), reported the issuance of two United States patents that significantly broaden the company's intellectual property leadership in the field of targeted anti-aminophospholipid agents.
Peregrine Pharmaceuticals, Inc. (Tustin, CA), a biopharmaceutical company with a portfolio of innovative, clinical stage products for the treatment of cancer and hepatitis C virus (HCV) infection, reported new research showing that a fusion protein approach that combines two proprietary Peregrine technology platforms -- its Vascular Targeting Agent (VTA) and anti-phospholipid (anti-PS) technologies -- has demonstrated significant anti-tumor potential.